News Releases

June 7, 2017
Synlogic Meets First Discovery Milestone in Partnership with AbbVie
–   Discoveries support next phase of collaboration with AbbVie –     Cambridge, Mass (Business Wire)  – Synlogic™ has completed the first phase of its ongoing collaboration with AbbVie. During this first discovery phase of the collaboration Synlogic has identified Synthetic...
June 2, 2017
Synlogic to Present at Jefferies 2017 Global Healthcare Conference
CAMBRIDGE, Mass. –( BUSINESS WIRE )–Synlogic announced today that its President and Chief Executive Officer, Jose Carlos Gutierrez-Ramos, Ph.D., will speak at the Jefferies 2017 Global Healthcare Conference on Friday, June 9th at 1:30 p.m. in New York City....
May 26, 2017
Synlogic and Mirna Investor Conference Call Replay
On May 16, 2017, Synlogic and Mirna Therapeutics held a conference call to discuss the proposed merger as well as Synlogic’s platform and pipeline assets. The replay can be accessed through the below link and conference ID. Webcast Link:  http://edge.media-server.com/m/p/zutpri3c Conference ID...
May 16, 2017
Synlogic and Mirna Therapeutics Agree to Merger
– Transaction Expected to Advance Synlogic’s Innovative Platform for the Discovery and Development of Novel Synthetic Biotic™ Medicines – – Synlogic Closes $42 Million of Series C Preferred Stock Financing by Leading Biotechnology Investors – – Combined Company Well-Capitalized with Approximately...
May 16, 2017
Synlogic and Mirna Investor Conference Call Information
Synlogic and Mirna Therapeutics will host a conference call to discuss the proposed transaction as well as Synlogic’s platform and pipeline assets on  May 16, 2017 at 8:30 AM ET . The live webcast can be accessed through the information below....
March 23, 2017
Synlogic to Present at 2017 American College of Medical Genetics and Genomics Annual Meeting
Cambridge, Mass (BUSINESS WIRE).  March 22 nd , 2017.  Synlogic™ Inc. today announced that the company will present preclinical data on two rare metabolic disease programs from its Synthetic Biotics™ platform at the American College of Medical Genetics and Genomics Annual Meeting from...
December 15, 2016
Synlogic Appoints COO and Head of Corporate Development
Experienced biotechnology leader, Sam Truex, joins Synlogic’s leadership team CAMBRIDGE, Mass., December 15, 2016 – CAMBRIDGE, Mass. – Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its proprietary synthetic biology and microbiome platform, today announced...
November 10, 2016
Synlogic Secures Patent on Proprietary Synthetic Probiotic Bacteria for the Treatment of Hyperammonemia
First Live  E. Coli  Nissle Bacterium Modified to Assimilate Ammonia Potential Treatment of Urea Cycle Disorders and Other Forms of Hyperammonemia CAMBRIDGE, Mass.–( BUSINESS WIRE )–Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its...
September 12, 2016
Synlogic Expands Leadership Team to Support Rapid Advancement of the First Synthetic Biotic Towards the Clinic
Company Appoints Seasoned Biotech Executives to Lead Finance, Clinical, Translational and Manufacturing Functions September 12, 2016 08:00 AM Eastern Daylight Time CAMBRIDGE, Mass.–( BUSINESS WIRE )–Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its...
August 29, 2016
Synlogic Proprietary Synthetic Biotic Receives FDA Orphan Drug Designation
The Company Has Developed The First Live  E. Coli  Nissle Bacterium Modified To Assimilate Ammonia For The Potential Treatment Of Urea Cycle Disorders CAMBRIDGE, Mass.–( BUSINESS WIRE )–Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its...
March 23, 2016
Synlogic Appoints an Industry Leader Nick Leschly to its Board of Directors
CAMBRIDGE, Mass., – March 23, 2016 –  Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its proprietary synthetic biology and microbiome platform, today announced the expansion of its Board of Directors with the appointment of Mr....
February 17, 2016
Synlogic Secures $40 Million in Series B Financing
Additional funding to accelerate the two lead Urea Cycle Disorder and Phenylketonuria pipeline programs to the clinic and expand the Synthetic Biotics platform CAMBRIDGE, Mass., – February 17, 2016 –  Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its...
Displaying 97 - 108 of 115